Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, Koroleva A, Skov Neergaard J, Velez Sanchez P, Wharton S, Wizert A, Kristensen LE, Group SS (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis
PlushCare : Best for Traditional Care Model PlushCare connects patients with their own primary care physician online, offering same-day appointments and nationwide access to GLP-1 prescriptions like Zepbound
(Practice point) Once an SGLT2i is initiated, it is reasonable to continue an SGLT2i even if the eGFR falls below 30 ml/min per 1.73 m2, unless it is not tolerated or kidney replacement therapy is initiated.(Practice point) SGLT2i have not been adequately studied in kidney transplant recipients, who may benefit from SGLT2i treatment, but are immunosuppressed and potentially at increased risk for infections
The average monthly weight loss on GLP-1 medications settles into a predictable pattern during this phase